Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1681 injection in patients with malignant solid tumors (Phase I/II, open-label, multicenter study)
CTR20244759Phase 2Active
- Sponsor
- Suzhou Shengdiya Biopharmaceuticals
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-1681 in Non-hematologic malignancy, sponsored by Suzhou Shengdiya Biopharmaceuticals. Started Feb 2025; status: active.
02
Drugs
SHR-1681
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on CTR20244759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244759.